Accelerated path closes for Moderna/Merck’s immunotherapy
Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.
Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
It’s back to school for biotech, with a packed conference schedule.
A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.